Use of pregabalin (sold as Lyrica®) has skyrocketed in recent years. Anecdotal reports indicate problematic use is becoming more common including amongst people who inject drugs.
In Australia, pregabalin is a commonly prescribed medicine, subsidised as an anti-epileptic and to treat neuropathic pain. It is often prescribed for the treatment of other conditions including musculoskeletal pain and generalised anxiety disorder. It is an effective medicine and has an important role in managing pain.
This seminar will discuss pregabalin, its benefits, potential for misuse and methods to reduce harms.
This pregabalin seminar is your opportunity to hear from the experts, ask questions and learn from each other.
When: Friday 14 June, 9.45 for a 10am sharp start to approx. 12noon
Where: Performance Space @ Library at the Dock, 107 Victoria Harbour Promenade, Docklands.
Cost: Free but places are limited so please register early
- Dr Shaun Greene is a clinical toxicologist and emergency physician based at the Austin Hospital. He is currently medical director of the Victorian Poisons Information Centre. Trained in London Shaun has a professional interest in psychoactive substances, including opioids.
- Dr Rose Crossin is a senior policy and research officer at Penington Institute. Previously a researcher at Turning Point, Rose is an author on one of only two major studies on pregabalin misuse and harms in Australia.
- Melanie Walker is the CEO of the Australian Injecting and Illicit Drug Users League (AIVL). She has extensive experience in public health, having worked in many senior positions including as the Deputy Chief Executive Officer of the Public Health Association of Australia.
Please note this seminar is being held at a new location in Docklands. Paid parking in the area is limited. The 11 and 48 trams stop nearby.